The eIg technology to generate Ig-like bispecific antibodies

Bispecific antibodies have emerged as therapeutic molecules with a multitude of modes of action and applications. Here, we present a novel approach to solve the light-chain problem for the generation of bispecific Ig-like antibodies using the second constant domain of IgE (EHD2) genetically modified...

Full description

Bibliographic Details
Published in:	mAbs
Main Authors:	Lennart Kühl, Nadine Aschmoneit, Roland E. Kontermann, Oliver Seifert
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-12-01
Subjects:	bispecific antibody hetEHD2 light chain problem MET EGFR HER3
Online Access:	https://www.tandfonline.com/doi/10.1080/19420862.2022.2063043

Similar Items

eIg-based bispecific T-cell engagers targeting EGFR: Format matters
by: Lennart Kühl, et al.
Published: (2023-12-01)

Trispecific eFab-eIg T-cell engagers targeting HER2 and HER3
by: Ann-Kathrin Löffler, et al.
Published: (2025-08-01)

Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma
by: Alan W Long, et al.
Published: (2024-04-01)

The physiological limits of bispecific monoclonal antibody tissue targeting specificity
by: Armin Sepp, et al.
Published: (2025-12-01)

Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma
by: Nami Tateyama, et al.
Published: (2022-11-01)

Structural and functional characterization of IgG- and non-IgG-based T-cell-engaging bispecific antibodies
by: Nishant Mohan, et al.
Published: (2024-05-01)

Generation of bispecific antibodies by structure-guided redesign of IgG constant regions
by: Yordkhwan W. Iwasaki, et al.
Published: (2023-01-01)

Bispecific antibody drug conjugates: Making 1+1>2
by: Yilin Gu, et al.
Published: (2024-05-01)

Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formats
by: Andreas V. Madsen, et al.
Published: (2023-12-01)

The Evolving Paradigm of Antibody–Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases
by: Peyton High, et al.
Published: (2024-07-01)

Co-targeting cancer stem-like cells and bulk cancer cells with a bispecific antibody
by: Shi Hu
Published: (2017-05-01)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
by: Iris Koopmans, et al.
Published: (2018-08-01)

Elucidating heavy/light chain pairing preferences to facilitate the assembly of bispecific IgG in single cells
by: Kamal Kishore Joshi, et al.
Published: (2019-10-01)

An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer
by: Latifa Zekri, et al.
Published: (2020-12-01)

Development of a Bispecific IgG1 Antibody Targeting BCMA and PDL1
by: Irene Cattaneo, et al.
Published: (2024-02-01)

Anti‐PD‐1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2‐Positive Gastric Cancer through Gasdermin B‐Cleavage Induced Pyroptosis
by: Wu Lin, et al.
Published: (2023-10-01)

A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib
by: Arturo Simoni-Nieves, et al.
Published: (2024-09-01)

Rapid Generation of Murine Bispecific Antibodies Using FAST-Ig<sup>TM</sup> for Preclinical Screening of HER2/CD3 T-Cell Engagers
by: Hikaru Koga, et al.
Published: (2024-01-01)

Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy
by: Amelia C. McCue, et al.
Published: (2024-12-01)

Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the CH1-Cλ interface
by: John D. Bagert, et al.
Published: (2023-12-01)

Bispecific antibodies: design, therapy, perspectives
by: Sedykh SE, et al.
Published: (2018-01-01)

Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies
by: Wen-Ting K. Tsai, et al.
Published: (2024-12-01)

Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodies
by: Kristina M.J. Aertker, et al.
Published: (2024-12-01)

Internal enhancement of DNA damage by a novel bispecific antibody‐drug conjugate‐like therapeutics via blockage of mTOR and PD‐L1 signal pathways in pancreatic cancer
by: Rui Cao, et al.
Published: (2019-02-01)

Bispecific antibodies and their use in applied research
by: Harshit Verma, et al.
Published: (2012-01-01)

EGFR-selective activation of CD27 co-stimulatory signaling by a bispecific antibody enhances anti-tumor activity of T cells
by: Vinicio Melo, et al.
Published: (2023-07-01)

Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers
by: Ammelie Svea Boje, et al.
Published: (2024-12-01)

RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties
by: Barnabas Nyesiga, et al.
Published: (2024-12-01)

Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
by: Gihoon You, et al.
Published: (2021-07-01)

Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release
by: Nadine Aschmoneit, et al.
Published: (2021-11-01)

The Blood of the HIV-Infected Patients Contains κ-IgG, λ-IgG, and Bispecific κλ-IgG, Which Possess DNase and Amylolytic Activity
by: Anna Timofeeva, et al.
Published: (2022-02-01)

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
by: Shengnan Yu, et al.
Published: (2019-08-01)

A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma
by: Alfred L. Garfall, et al.
Published: (2025-07-01)

HER2-CD3-Fc Bispecific Antibody-Encoding mRNA Delivered by Lipid Nanoparticles Suppresses HER2-Positive Tumor Growth
by: Liang Hu, et al.
Published: (2024-07-01)

GlycoTAIL and FlexiTAIL as Half-Life Extension Modules for Recombinant Antibody Fragments
by: Oliver Seifert, et al.
Published: (2022-05-01)

Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours
by: Manley T. F. Huang, et al.
Published: (2022-12-01)

Developability considerations for bispecific and multispecific antibodies
by: Alaa Amash, et al.
Published: (2024-12-01)

Shortened Hinge Design of Fab x sdAb-Fc Bispecific Antibodies Enhances Redirected T-Cell Killing of Tumor Cells
by: Shuyu Huang, et al.
Published: (2022-09-01)

Efficient production of bispecific antibody by FAST-IgTM and its application to NXT007 for the treatment of hemophilia A
by: Hikaru Koga, et al.
Published: (2023-12-01)

Common light chain chickens produce human antibodies of high affinity and broad epitope coverage for the engineering of bispecifics
by: Kathryn H. Ching, et al.
Published: (2021-01-01)